Key result
Stable angina linked to ~2-fold higher serum FGF21, though levels do not track CAD severity.
Why the study?
Increased circulating fibroblast growth factor 21 (FGF21) concentrations are associated with obesity, metabolic disorder, and atherosclerosis, but the relationship between FGF21 and coronary artery disease (CAD) development and severity is controversial.
Case-Control (n=118)
Single-blind
No
Answers are grounded in this paper and cite their sources.
FGF21 elevation does not support CAD severity assessment; leaves open its diagnostic utility in stable angina.
Background: Recent studies have shown that increased circulating concentrations of fibroblast growth factor 21 (FGF21) are associated with obesity, metabolic disorder, and atherosclerosis. However the relationship between FGF21 and coronary artery disease (CAD) is controversial This study was planned to investigate the role of FGF21 in CAD development and CAD severity. Methods: Seventy-eight patients with stable angina pectoris (SAP) (lesion positive) and 40 control patients (lesion negative) with similar cardiovascular risk factors were included in the study. Serum FGF21 levels were measured by ELISA method. CAD severity was evaluated by using SYNTAX and GENSINI risk scores. Results: FGF21 concentrations were found significantly higher in the SAP group than in the control group. [101.18 ± 141.62 vs. 47.93 ± 58.74 pg/mL; p = 0.03], no correlation was found between the SYNTAX (r = 0.146 and p = 0.134) and GENSINI (r = 0.211 and p = 0.084) scores with serum FGF21 levels. There was a negative relationship between serum FGF21 and serum HDL-C levels in correlation analysis (r = - 0.272; p = 0.026). Conclusions: The serum FGF21 levels are different between SAP and control patients. FGF21 is a marker for CAD diagnosis, but not for the evaluation of CAD severity.
No takes yet. Share an insight, caveat, or question.
Nar et al. (2021) conducted a case-control in Coronary artery disease / Stable angina pectoris (n=118). Stable angina pectoris (coronary artery disease) vs. Control patients without atherosclerotic lesions on coronary angiography was evaluated on Serum fibroblast growth factor 21 (FGF21) concentration (pg/mL) (p=0.03). Serum FGF21 levels were significantly higher in stable angina pectoris patients than controls (101.18 vs 47.93 pg/mL; p=0.03), but did not correlate with SYNTAX or GENSINI CAD severity scores.
Synapse has enriched 10 related papers. Consider them for comparative context: